The pregnane X receptor: From bench to bedside

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 7, 2008, Pages 895-908

  Ma, Xiaochao ^a   Idle, Jeffrey R ^b   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Clinical implications; Nuclear receptor; Pregnane X receptor; PXR humanized mouse; Pxr null mouse

Indexed keywords

AMPRENAVIR; ANTIFIBROTIC AGENT; BUDESONIDE; COLECALCIFEROL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DRUG METABOLIZING ENZYME; ERGOCALCIFEROL; FARNESOID X RECEPTOR; GLUCURONOSYLTRANSFERASE; HYPERICUM PERFORATUM EXTRACT; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; MIDAZOLAM; NELFINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; PARACETAMOL; PREGNANE X RECEPTOR; PROTEINASE INHIBITOR; RIFAMPICIN; RIFAXIMIN; SAQUINAVIR; STEROID HORMONE; TAMOXIFEN; TRIACYLGLYCEROL; UNINDEXED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ANXIETY DISORDER; AREA UNDER THE CURVE; BILE ACID METABOLISM; BILE SECRETION; BLEEDING; CANCER RESISTANCE; CHOLESTATIC HEPATITIS; DEPRESSION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; ENTERITIS; ENZYME ACTIVATION; FATTY LIVER; FETUS DEATH; FETUS MALFORMATION; FEVER; HEADACHE; HOMEOSTASIS; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KNOCKOUT MOUSE; LIVER FAILURE; LIVER METABOLISM; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; METABOLIC BONE DISEASE; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PRIMARY BILIARY CIRRHOSIS; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SLEEP DISORDER; SPECIES DIFFERENCE; STEROID METABOLISM; TRAVELLER DIARRHEA; TUBERCULOSIS; VITAMIN D METABOLISM;

ANIMALS; BILE ACIDS AND SALTS; DRUG INTERACTIONS; HOMEOSTASIS; HUMANS; IRRITABLE BOWEL SYNDROME; LIVER DISEASES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PHARMACEUTICAL PREPARATIONS; RECEPTORS, STEROID; STEROIDS; VITAMIN D;

MAMMALIA; MUS;

EID: 49649102377     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.7.895     Document Type: Review

References (112)

1. Kliewer SA, Moore JT, Wade L, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998;92(I):73-82
2. Lehmann JM, Mckee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102(5):1016-23
3. Blumberg B, Sabbagh W Jr, Juguilon H, et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998;12(20):3195-205
4. Moore LB, Maglich JM, Mckee DD, et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 2002;16(5):977-86
5. Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res 2002;43(3):359-64
6. Kliewer SA. The nuclear pregnane X receptor regulates xenobiotic detoxification. J Nutr 2003;133(7 Suppl):S2444-7
7. Rosenfeld JM, Vargas R Jr, Xie W, et al. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol Endocrinol 2003;17(7):1268-82
8. Poso A, Honkakoski P. Ligand recognition by drug-activated nuclear receptors PXR and CAR: structural, site-directed mutagenesis and molecular modeling studies. Mini Rev Med Chem 2006;6(8):937-47
9. Honkakoski P, Sueyoshi T, Negishi M. Drug-activated nuclear receptors CAR and PXR. Ann Med 2003;35(3):172-82
10. Carnahan VE, Redinbo MR. Structure and function of the human nuclear xenobiotic receptor PXR. Curr Drug Metab 2005;6(4):357-67
11. Jacobs MN, Dickins M, Lewis DF. Homology modelling of the nuclear receptors: human oestrogen receptorbeta (hERbeta), the human pregnane-X-receptor (PXR), the Ah receptor (AhR) and the constitutive androstane receptor (CAR) ligand binding domains from the human oestrogen receptor alpha (hERalpha) crystal structure, and the human peroxisome proliferator activated receptor alpha (PPARalpha) ligand binding domain from the human PPARgamma crystal structure. J Steroid Biochem Mol Biol 2003;84(2-3):117-32
12. Kliewer SA, Goodwin B, Wilson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002;23(5):687-702
13. Staudinger JL, Ding X, Lichti K. Pregnane X receptor and natural products: beyond drug-drug interactions. Expert Opin Drug Metab Toxicol 2006;2(6):847-57
14. Landes N, Birringer M, Brigelius-Flohe R. Homologous metabolic and gene activating routes for vitamins E and K. Mol Aspects Med 2003;24(6):337-44
15. Tabb MM, Sun A, Zhou C, et al. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 2003;278(45):43919-27
16. Pacyniak EK, Cheng X, Cunningham ML, et al. The flame retardants, polybrominated diphenyl ethers, are pregnane X receptor activators. Toxicol Sci 2007;97(1):94-102
17. Coumoul X, Diry M, Barouki R. PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides. Biochem Pharmacol 2002;64(10):1513-9
18. Masuyama H, Hiramatsu Y, Kunitomi M, et al. Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate Pregnane X receptor-mediated transcription. Mol Endocrinol 2000;14(3):421-8
19. Goodwin B, Gauthier KC, Umetani M, et al. Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc Natl Acad Sci USA 2003;100(1):223-8
20. Mnif W, Pascussi JM, Pillon A, et al. Estrogens and antiestrogens activate hPXR. Toxicol Lett 2007;170(1):19-29
21. Guzelian J, Barwick JL, Hunter L, et al. Identification of genes controlled by the pregnane X receptor by microarray analysis of mRNAs from pregnenolone 16alpha-carbonitrile-treated rats. Toxicol Sci 2006;94(2):379-87
22. Xie W, Barwick JL, Simon CM, et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 2000;14(23):3014-23
23. Gellner K, Eiselt R, Hustert E, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001;11(2):111-21
24. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann Rev Pharmacol Toxicol 1999;39:1-17
25. Mackenzie PI, Gregory PA, Gardner-Stephen DA, et al. Regulation of UDP glucuranosyltransferase genes. Curr Drug Metab 2003;4(3):249-57
26. Falkner KC, Pinaire JA, Xiao GH, et al. Regulation of the rat glutathione S-transferase A2 gene by glucocorticoids: involvement of both the glucocorticoid and pregnane X receptors. Mol Pharmacol 2001;60(3):611-9
27. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;276(18):14581-7
28. Teng S, Jekerle V, Piquette-Miller M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos 2003;31(11):1296-9
29. Staudinger J, Liu Y, Madan A, et al. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos 2001;29(11):1467-72
30. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002;30(7):795-804
31. Zhu Z, Kim S, Chen T, et al. Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 2004;9(6):533-40
32. Luo G, Guenthner T, Gan LS, et al. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 2004;5(6):483-505
33. Xie W, Barwick JL, Downes M, et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000;406(6794):435-9
34. Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 2001;98(6):3369-74
35. Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 1998;95(21):12208-13
36. Iyer M, Reschly EJ, Krasowski MD. Functional evolution of the pregnane X receptor. Expert Opin Drug Metab Toxicol 2006;2(3):381-97
37. Watkins RE, Noble SM, Redinbo MR. Structural insights into the promiscuity and function of the human pregnane X receptor. Curr Opin Drug Discov Devel 2002;5(1):150-8
38. Xue Y, Moore LB, Orans J, et al. Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol 2007;21(5):1028-38
39. Ma X, Shah Y, Cheung C, et al. The Pregnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos 2007;35(2):194-200
40. Zhang H, Leculyse E, Liu L, et al. Rat pregnane X receptor: molecular cloning, tissue distribution, and xenobiotic regulation. Arch Biochem Biophys 1999;368(1):14-22
41. Gong H, Singh SV, Singh SP, et al. Orphan nuclear receptor pregnane X receptor sensitizes oxidative stress responses in transgenic mice and cancerous cells. Mol Endocrinol 2006;20(2):279-90
42. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-5
43. Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42(9):819-50
44. Reimers D, Jezek A. The simultaneous use of rifampicin and other antitubercular agents with oral contraceptives. Prax Pneumol 1971;25(5):255-62
45. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59(1):7-13
46. Polk RE, Brophy DF, Israel DS, et al. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 2001;45(2):502-8
47. Grub S, Bryson H, Goggin T, et al. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 2001;57(2):115-21
48. Website: Herbs at a glance: St. John's Wort. Available from: http://nccam.nih.gov/health/stjohnswort/ [Last access 29 February 2008]
49. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort. Lancet 2000;355(9203):548-9
50. Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97(13):7500-2
51. Murakami Y, Tanaka T, Murakami H, et al. Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A. Br J Clin Pharmacol 2006;61(6):671-6
52. Mai I, Bauer S, Perloff ES, et al. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004;76(4):330-40
53. Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology 2004;40(1):6-9
54. Crippin JS. Acetaminophen hepatotoxicity: potentiation by isoniazid. Am J Gastroenterol 1993;88(4):590-2
55. Szymanska JA, Swietlicka EA, Piotrowski JK, et al. Effects of 3-methylcholanthrene or diethyl maleate on the hepatotoxicity of acetaminophen. J Appl Toxicol 1992;12(6):415-9
56. Guo GL, Moffit JS, Nicol CJ, et al. Enhanced acetaminophen toxicity by activation of the pregnane X receptor. Toxicol Sci 2004;82(2):374-80
57. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004;89(11):5387-91
58. Coates ME. Requirements of different species for vitamins. Proc Nutr Soc 1968;27(2):143-8
59. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80(6 Suppl):S1678-88
60. Pascussi JM, Robert A, Nguyen M, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005;115(1):177-86
61. Xu Y, Hashizume T, Shuhart MC, et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol 2006;69(1):56-65
62. D'Erasmo E, Ragno A, Raejntroph N, et al. Drug-induced osteomalacia. Recenti Prog Med 1998;89(10):529-33
63. Williams SE, Wardman AG, Taylor GA, et al. Long term study of the effect of rifampicin and isoniazid on vitamin D metabolism. Tubercle 1985;66(1):49-54
64. Brodie MJ, Boobis AR, Dollery CT, et al. Rifampicin and vitamin D metabolism. Clin Pharmacol Ther 1980;27(6):810-4
65. Igarashi M, Yogiashi Y, Mihara M, et al. Vitamin K induces osteoblast differentiation through PXR-mediated transcriptional control of the Msx2 gene. Mol Cell Biol 2007;27(22):7947-54
66. Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000;102(6):731-44
67. Inoue Y, Yu AM, Inoue J, et al. Hepatocyte nuclear factor 4alpha is a central regulator of bile acid conjugation. J Biol Chem 2004;279(4):2480-9
68. Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Ann Rev Physiol 2006;68:159-91
69. Zhang J, Huang W, Qatanani M, et al. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J Biol Chem 2004;279(47):49517-22
70. Li T, Chiang JY. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. Am J Physiol Gastrointest Liver Physiol 2005;288(1):G74-84
71. Hoensch HP, Balzer K, Dylewizc P, et al. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol 1985;28(4):475-7
72. Galeazzi R, Lorenzini I, Orlandi F. Rifampicin-induced elevation of serum bile acids in man. Dig Dis Sci 1980;25(2):108-12
73. Taillan B, Chichmanian RM, Fuzibet JG, et al. Jaundice caused by rifampicin: 3 cases. Rev Med Interne 1989;10(5):409-11
74. Bachs L, Pares A, Elena M, et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992;102(6):2077-80
75. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002;50(3):436-9
76. Zhou J, Zhai Y, Mu Y, et al. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J Biol Chem 2006;281(21):15013-20
77. Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008;134(2):556-67
78. Dai G, He L, Bu P, et al. Pregnane X receptor is essential for normal progression of liver regeneration. Hepatology 2008;47(4):1277-87
79. Mitro N, Vargas L, Romeo R, et al. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett 2007;581(9):1721-6
80. Morere P, Nouvet G, Stain JP, et al. Information obtained by liver biopsy in 100 tuberculous patients. Sem Hop 1975;51(31-34):2095-102
81. Truhaut R, Claude JR, Warnet JM, et al. Liver steatogenic power of high doses of rifampicin in rats. C R Acad Sci Hebd Seances Acad Sci D 1978;286(6):493-7
82. Piriou A, Maissiat R, Jacqueson A, et al. Ultrastructural changes in the parenchymal liver cells of rats treated with high doses of rifampicin. Br J Exp Pathol 1987;68(2):201-7
83. Zhai Y, Pai HV, Zhou J, et al. Activation of pregnane X receptor disrupts glucocorticoid and mineralocorticoid homeostasis. Mol Endocrinol 2007;21(1):138-47
84. Buters JT, Korzekwa KR, Kunze KL, et al. cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Dispos 1994;22(5):688-92
85. Fayer JL, Petullo DM, Ring BJ, et al. A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro. J Pharmacol Toxicol Methods 2001;46(2):117-23
86. Konishi H, Tanaka K, Minouchi T, et al. Urinary 6beta-hydroxycortisol/ 17-hydroxycorticosteroids ratio as a measure of hepatic CYP3A4 capacity after enzyme induction. Ann Clin Biochem 2004;41(Pt 4):335-7
87. Niwa T, Yabusaki Y, Honma K, et al. Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica 1998;28(6):539-47
88. Lee AJ, Kosh JW, Conney AH, et al. Characterization of the NADPH-dependent metabolism of 17beta-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. J Pharmacol Exp Ther 2001;298(2):420-32
89. Badawi AF, Cavalieri EL, Rogan EG. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism 2001;50(9):1001-3
90. Yu AM, Fukamachi K, Krausz KW, et al. Potential role for human cytochrome P450 3A4 in estradiol homeostasis. Endocrinology 2005;146(7):2911-9
91. Website: Safety information of rifampicin from intergovernmental organizations, International Program on Chemical Safety. Available from: http://www.inchem.org/documents/pims/pharm/rifam.htm [Last access 29 February 2008]
92. Dring MM, Goulding CA, Trimble VI, et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 2006;130(2):341-8
93. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004;127(1):26-40
94. Martinez A, Marquez A, Mendoza J, et al. Role of the PXR gene locus in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13(12):1484-7
95. Shah YM, Ma X, Morimura K, et al. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol 2007;292(4):G1114-22
96. Chen C, Shah YM, Morimura K, et al. Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab 2008;7(2):135-47
97. Maier A, Zimmermann C, Beglinger C, et al. Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br J Pharmacol 2007;150(3):361-8
98. Laustsen G, Wimmett L. 2004 drug approval highlights: FDA update. Nurse Pract 2005;30(2):14-29
99. Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin 2005;21(8):1165-9
100. Gionchetti P, Rizzello F, Morselli C, et al. Management of inflammatory bowel disease: does rifaximin offer any promise? Chemotherapy 2005;51(Suppl 1):96-102
101. Guslandi M, Petrone MC, Testoni PA. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis 2006;12(4):335
102. Ma X, Shah YM, Guo GL, et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007;322(1):391-8
103. Harmsen S, Meijerman I, Beijnen JH, et al. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev 2007;33(4):369-80
104. Chen Y, Tang Y, Wang MT, et al. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res 2007;67(21):10361-7
105. Dotzlaw H, Leygue E, Watson P, et al. The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin Cancer Res 1999;5(8):2103-7
106. Masuyama H, Hiramatsu Y, Kodama J, et al. Expression and potential roles of pregnane X receptor in endometrial cancer. J Clin Endocrinol Metab 2003;88(9):4446-54
107. Pfrunder A, Gutmann H, Beglinger C, et al. Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. J Pharm Pharmacol 2003;55(1):59-66
108. Miki Y, Suzuki T, Kitada K, et al. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res 2006;66(1):535-42
109. Zhou J, Liu M, Zhai Y, et al. The antiapoptotic role of pregnane x receptor in human colon cancer cells. Mol Endocrinol 2008;22(4):868-80
110. Marek CJ, Tucker SJ, Konstantinou DK, et al. Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem J 2005;387(Pt 3):601-8
111. Haughton EL, Tucker SJ, Marek CJ, et al. Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. Gastroenterology 2006;131(1):194-209
112. Gong H, Singh SV, Singh SP, et al. Orphan nuclear receptor pregnane X receptor sensitizes oxidative stress responses in transgenic mice and cancerous cells. Mol Endocrinol 2006;20(2):279-90